Serum Manufacturer Briefs Run Into Three Hard Ceilings
A serum brief usually arrives as a list of percentages: 0.5% retinol, 10% glycolic, a peptide complex at supplier use level. Some of those numbers are not the brand’s to choose. A serum manufacturer works to a concentration ceiling set in Brussels, a percentage-and-pH convention echoed in FDA guidance, and a claims ceiling set by what the bottle says rather than what is in it. The nearest has a date: 1 May 2027, when non-compliant vitamin A products stop being saleable in the EU.
The retinol ceiling has a deadline, and it is closer than a development cycle
Commission Regulation (EU) 2024/996 restricts Retinol, Retinyl Acetate and Retinyl Palmitate to a maximum of 0.05% retinol equivalent (RE) in body lotion and 0.3% RE in other leave-on and rinse-off products. Any product containing those substances also has to carry the wording “Contains Vitamin A. Consider your daily intake before use.”
The transition runs in two stages and brands routinely read only the first. Since 1 November 2025 a non-compliant product cannot be placed on the Union market. From 1 May 2027 it cannot be made available there at all, which reaches stock already in a distributor’s warehouse or on a shelf. Summaries of the amendment describe the same two-stage structure.
For a US brand with EU distribution that second date is the one that bites, and it is under six months away. Reformulating is not a label change: a different vitamin A level, or a move to an encapsulated form, shifts the viscosity and the antioxidant system, and the stability work that follows takes longer than the filling.
The same regulation set levels for alpha-arbutin (2% face cream, 0.5% body lotion) and kojic acid (1%, face and hand products). Those dates have already passed.
The exfoliating acid ceiling is a convention, not a statute — and it still governs the label
The US has no equivalent cap on alpha hydroxy acids. What exists instead is a safety conclusion that behaves like one. FDA’s AHA page records the Cosmetic Ingredient Review Expert Panel’s conclusion that glycolic and lactic acid products are safe for consumer use if the AHA concentration is 10 percent or less, the final product has a pH of 3.5 or greater, and the product is formulated or labeled for daily sun protection.
Those three conditions travel together, which is the part briefs get wrong. A 10% glycolic serum formulated down to pH 2.8 is not “within the 10% guidance” — it has left the conclusion that guidance rests on. FDA studies found that after four weeks of AHA application, volunteers’ sensitivity to UV-induced skin reddening rose by 18 percent and sensitivity to UV-induced cellular damage doubled on average, reversing about a week after stopping. That is why FDA’s January 2005 guidance recommends a “Sunburn Alert” statement on AHA products.
The claims ceiling is the one that changes what the product legally is
The third ceiling has nothing to do with concentration. Under the FD&C Act a cosmetic is defined by intended use — cleansing, beautifying, promoting attractiveness or altering the appearance — and a drug in part as an article intended to affect the structure or any function of the body. FDA’s explainer says where intended use comes from: claims on the label, in advertising and on the website; consumer perception built on the product’s reputation; and ingredients with a well-known therapeutic use.
The agency’s anti-aging page draws the line with one example worth keeping. A product intended to make lines and wrinkles less noticeable by moisturizing the skin is a cosmetic. One intended to remove wrinkles or increase the skin’s production of collagen is a drug or a medical device. Same jar, different sentence. And “cosmeceutical” rescues nothing in between: FDA states that the term has no meaning under the law.
This matters at the manufacturing stage: the claim decides the regulatory pathway, and the pathway decides the records and the label format. A founder who signs off formulation and writes the copy afterwards has sequenced the project backwards.
What to settle before the first batch
- Declare your markets before the formula is locked. EU distribution makes the 0.3% RE ceiling and the vitamin A warning inputs to the brief, not a later edit.
- Audit vitamin A stock against 1 May 2027, not just the 2025 date. Inventory already in the EU channel is in scope.
- Specify pH alongside acid percentage. The percentage alone does not describe the product.
- Write the hero claim before the formulation review and check it against FDA’s structure-or-function line.
- Ask where responsibility sits. A US manufacturer can build to EU limits but cannot be your EU Responsible Person, and the safety assessment is separate commissioned work.
Where a manufacturer fits
Moe’s Group formulates, fills and labels skin care at a single FDA-registered facility in Chatsworth, California (FEI 3041507202 — registered, not approved; FDA does not approve cosmetics). Ready-made formulas start at a 200-unit minimum and custom formulation at 1,000 units, skin care capacity runs to a million units a month, and production is typically about seven days from order once the formulation is approved, with larger first orders taking longer.
Before any of that, do the twenty-minute version of this article: list the markets, list the restricted actives, and write the claim intended for the front of the bottle. If a serum concept is at that stage, the product inquiry form is where to start.
Moe’s Group Newsroom
